CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0856 (clinicaltrials.gov NCT No: NCT01431209)
Title:A Phase 2 Multicenter, investigator initiated study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non-Hodgkin Lymphoma
Principal Investigator:Yasuhiro Oki
Treatment Agent:INCB018424
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if ruxolitinib phosphate
(ruxolitinib) can help to control lymphoma. The safety of this drug will also
be studied.

Ruxolitinib is designed to block the activity of proteins in the body (called
JAKs) that have been associated with cancer growth and survival. Blocking
these proteins may cause the cancer cells to die.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:INCB018424
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Incyte Corporation
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yasuhiro Oki
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults